Table 2.

Clinicopathological features of the study cohort

Case no.	Sex/age	Site of biopsy	Stage	IPI	Therapy	Response	Other sites involved	Follow-up
								Status	Months
1	M/41	Oropharynx	III/IV	High risk	CHOP	NR	–	D	2
2	M/47	Nasopharynx	I/II	Low risk	RT	CR	–	A	66
3	M/31	Nasal cavity	I/II	Low risk	RT	NR	–	D	7
4	M/42	Nasal cavity	I/II	Low risk	RT	CR	–	D	30
5	M/33	Nasal cavity	I/II	Low risk	RT	PR	–	D	6
6	M/39	Nasal cavity	I/II	Low risk	RT	CR	–	D	53
7	F/28	Nasal cavity	I/II	Low risk	CHOP + RT	CR	–	A	60
8	F/36	Nasal cavity	I/II	Low risk	RT	NR	Orbit	D	6
9	M/41	Nasal cavity	I/II	Low risk	CHOP	NR	–	D	8
10	M/58	Duodenum	I/II	Low risk	CHOP	PR	–	D	24
11	M/48	Nasal cavity	III/IV	High risk	CHOP-like	PR	Testis	D	6
12	F/60	Skin	I/II	High risk	CHOP	NR	Nasal cavity	D	22
13	M/28	Eyelid	I/II	Low risk	CHOP-like	NR	–	D	2

M male, F female, IPI international prognostic index, CHOP cyclophosphamide, doxorubicin, vincristin, prednisone; RT, radiotherapy, CR complete regression, PR partial regression, NR no response, A alive, D dead

Low risk: IPI 0-1, High risk: IPI ≥ 2